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Introduction 
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like 
episodes (MELAS) syndrome is a rare neurodegenerative disorder 
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Purpose: Magnetic resonance spectroscopy (MRS) is a diagnostic tool used to detect abnormal 
accumulation of lactate in the brain parenchyma in various metabolic diseases. This study evalu-
ated the clinical roles of brain MRS in the initial assessment of mitochondrial encephalomyopa-
thy, lactic acidosis, and stroke-like episodes (MELAS) caused by impairment of the mitochondrial 
respiratory chain. 
Methods: Twenty-five patients with the A3243G mutation among 34 MELAS patients referred to 
the pediatric neurology clinic of Gangnam Severance Hospital between January 2006 and De-
cember 2020 were included. In this retrospective study, demographic, clinical, laboratory (serum 
lactate and lactate-to-pyruvate ratio), magnetic resonance imaging (MRI), and initial MRS (pres-
ence of lactate peak and abnormal N-acetylaspartate [NAA]) data were reviewed. 
Results: Brain MRI showed cortical lesions in 24 of 25 genetically confirmed A3243G MELAS pa-
tients with neurologic symptoms in this study. On MRS, 18 patients (72%) had increased lactate 
peaks, depicting anaerobic energy metabolism, and 17 patients (68%) had decreased NAA levels, 
indicating neuronal integrity. Ten patients underwent MRS in the acute stage (within 2 weeks of 
symptoms). Unlike patients who underwent MRS more than 2 weeks after symptom onset, a lac-
tate peak on MRS was observed in all patients in the acute stage (P=0.011). 
Conclusion: Elevated lactate peaks in acute cerebral infarctions are highly suggestive of mito-
chondrial encephalopathy. MRS alone is insufficient to diagnose MELAS, but it is valuable as a 
noninvasive supplemental diagnostic tool in combination with genetic testing. 
Keywords: Magnetic resonance spectroscopy; Mitochondrial encephalomyopathies; MELAS syn-
drome; Mitochondrial diseases; Acidosis, lactic  
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caused by the impairment of the mitochondrial respiratory chain. 
Approximately 80% of cases have an A to G mutation at nucleotide 
3243 (A3243G) in the mitochondrial DNA molecule (MT-TL1), 
and heteroplasmy causes different mutational burdens within tis-
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sues, resulting in diverse clinical phenotypes. Patients usually pres-
ent with stroke-like episodes (hemianopia, cortical blindness, and 
dysarthria), seizures, recurrent headaches, or muscle weakness. El-
evated lactate levels in blood and cerebrospinal fluid (CSF) and a 
change in the lactate-to-pyruvate ratio indicate respiratory chain 
dysfunction [1-3]. Typical magnetic resonance imaging (MRI) 
findings in an acute stroke-like episode of MELAS include cortical 
lesions. Magnetic resonance spectroscopy (MRS) is a noninvasive 
method that reveals metabolic information regarding brain tissue. 
Increased lactate levels reflect anaerobic glycolysis, and N-acetylas-
partate (NAA) is a marker of neuronal integrity that represents 
neuronal injury associated with infarction. MRS has been used to 
diagnose stroke-like episodes in MELAS, with elevated lactate 
peaks and low NAA. Several researchers have previously reported 
that MRS is a useful tool for monitoring the progress of disease in 
patients with mitochondrial disorders [4-7]. This study aimed to 
evaluate the role of MRS in the initial assessment of MELAS. 
Materials and Methods 
The data of MELAS patients who were admitted to the pediatric 
neurology department at Gangnam Severance Hospital (Seoul, 
Korea) between January 2006 and December 2020 were reviewed. 
In total, 34 patients had findings compatible with the MELAS clin-
ical diagnostic criteria, as enumerated by Bernier et al. [8]. This 
was a retrospective study of patients with MELAS who met the 
following inclusion criteria: genetically confirmed diagnosis of a 
pathogenic variant associated with MEL AS (MT-TL1, 
m.3243A > G) and MRS performed at our center. Mutation carri-
ers without neurological symptoms were excluded. 
To identify the A3243G mutation, polymerase chain reaction 
amplification and restriction fragment length polymorphism anal-
ysis of total DNA extracted from leukocytes were performed. 
Based on this analysis, 25 patients with pathogenic mutations were 
included among the 34 symptomatic patients in this study. Demo-
graphic, clinical, laboratory, and MRI data were reviewed. This 
study was approved by the Institutional Review Board of the 
Gangnam Severance Hospital, Yonsei University College of Medi-
cine(3-2017-0168). Informed consent for this retrospective study 
was waived by the board. 
1. Mitochondrial characteristics of MELAS with A3243G 
The laboratory tests consisted of blood lactate level (normal < 2 
mmol/L) and the lactate-to-pyruvate ratio (normal < 25). Muscle 
biopsy samples were obtained from some patients and processed 
through routine morphological and histochemical staining, includ-
ing periodic acid-Schiff, modified Gomori trichrome, ATPase 9.4, 
nicotinamide adenine dinucleotide tetrazolium reductase, and suc-
cinate dehydrogenase stains. All samples were examined for chang-
es such as pleoconia and megaconia using electron microscopy. We 
investigated the initial MRS data to diagnose mitochondrial dis-
ease. MRS was performed on a GE 750 W 3.0T scanner (GE Med-
ical Systems, Milwaukee, WI, USA) with a 16-channel head-neck 
combined coil including T2-weighted sequences to obtain lactate 
at 1.3 ppm and NAA at 2.02 ppm. The voxels were placed in the 
frontal and occipital gray matter and basal ganglia of the bilateral 
hemispheres. 
The clinical severity of the patients was graded as follows: mild, 
self-ambulatory, with or without independence for daily activities; 
moderate, full-time wheelchair-bound, or partially dependent for 
daily activities, with the ability to engage in brief communication; 
and severe, bedridden, totally dependent for daily activities, or 
dead. All analyses were conducted using SPSS version 22.0 (IBM 
Corp., Armonk, NY, USA). Categorical variables were compared 
using the chi-square test and the Fisher exact test. Differences were 
considered statistically significant at a P value of < 0.05.  
Results 
1. Demographics and mitochondrial characteristics of 
patients with A3243G MELAS 
To evaluate the role of MRS in the initial evaluation process for the 
diagnosis of MELAS, this study adopted a retrospective design in-
volving a total of 25 patients (13 boys/men and 12 girls/women) 
who presented with neurological symptoms and in whom a genet-
ic analysis identified the pathogenic variant A3243G in MT-TL1 
(Table 1). The median age upon first clinical presentation was 13.3 
years (range, 0.2 to 45.6), and the median time interval from the 
first clinical presentation to the diagnosis of MELAS was 4.8 
months. The first symptoms of the disease were seizures (36%), 
visual impairment (28%), and motor weakness (18%). All patients 
exhibited neurological symptoms, followed by symptoms involv-
ing the orbital, endocrine, cardiac, auditory, psychological, myocar-
dial, gastrointestinal, and renal systems. 
The median serum lactate level was 4.3 mmol/L (range, 0.9 to 
13.5), and 92% of patients had a value of 2 mmol/L or higher. An 
elevated lactate-to-pyruvate ratio was found in only 52% of the pa-
tients (Table 2). 
2. MRI findings in patients with A3243G MELAS 
MRI studies performed to assess acute neurologic episodes identi-
fied cortical lesions in 24 (96%) of the 25 patients. Seventeen pa-
tients (68%) showed old infarctions with volume loss and diffuse 
cerebral atrophy, and 16 patients (64%) demonstrated diffuse cere-
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bellar atrophy. Nine patients (36%) had lesions in the basal ganglia, 
and two patients (8%) had lesions in the thalamus. 
3. MRS 
Remarkably, the MRS results did not show statistically significant 
differences between patients in whom MELAS was genetically 
confirmed and those without genetic confirmation (Table 3). 
MRS alone was insufficient for identifying patients with MELAS 
as an initial diagnostic marker. 
Increased lactate peaks were observed in 18 of 25 MRS studies 
(72%), and decreased NAA peaks were observed in 17 (68%) 
(Table 2). The acute stage was defined as clinical staging within the 
first 2 weeks of neurologic symptoms [9,10]. MRS studies were 
performed in the acute stage in 10 of the 25 patients with A3243G 
after neurologic episodes (seizures in three patients, visual distur-
bances in three patients, confusion in two patients, motor weak-
ness in one patient, and headache in one patient). Fifteen of the 25 
initial MRS studies were performed to screen patients with mito-
chondrial disease who did not show acute neurologic deteriora-
tion. Elevated lactate peaks were found in all 10 genetically con-
firmed MELAS patients in the acute stage with neurological symp-
toms, whereas they were found in eight of 15 patients (53%) who 
underwent MRS more than 2 weeks after acute episodes 
(P= 0.011) (Fig. 1). 
Table 1. Clinical characteristics of MELAS (A3243G) patients (n=25)
Characteristic Value
Sex (male:female) 0.55
Age at first clinical presentations (yr) 14.2±10.9
Age at diagnosis of MELAS (yr) 16.7±10.6
Time interval from first clinical presentation to the di-
agnosis of MELAS (yr)
0.9±1.3
Familial history of mitochondrial disease 4 (16)
Presentation symptoms at disease onset
 Seizure 9 (36)
 Visual disturbance 7 (28)
 Motor weakness 4 (16)
 Headache 2 (8)
 Loss of consciousness 2 (8)
 Delayed development 1 (4)
Organ involvement
 Central nervous system 25 (100)
 Endocrinologic 16 (64)
 Hearing 15 (60)
 Myopathy 14 (56)
 Eye 13 (52)
 Cardiologic 13 (52)
 Psychological 11 (44)
 Gastrointestinal system 9 (36)
 Renal system 8 (32)
Values are presented as mean±standard deviation or number (%).
MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like 
episodes.
Table 2. Mitochondrial characteristics of MELAS (A3243G) patients 
(n=25)
Characteristic Value
Serum lactate, initial (mmol/L) 4.3 (0.9–13.5)
 Lactic acidosis (>2 mmol/L) 23 (92)
Serum lactate-to-pyruvate ratio, initial 27.5 (11.3–52.8)
 Increased (>25) 13 (52)
Magnetic resonance imaging
 Infarction 24 (96)
 Cortex signal abnormality 24 (96)
 Diffuse cerebral atrophy 17 (68)
 Cerebellar atrophy 16 (64)
 Basal ganglia signal abnormality 9 (36)
 Thalamus signal abnormality 2 (8)
 White matter signal abnormality 19 (76)
Magnetic resonance spectroscopy
 Increased lactate peak 18 (72)
 Decreased NAA 17 (68)
Muscle biopsy obtained (n=7) 7 (28)
 Light microscopic changes (+) 3 (43)
 Electron microscopic changes (+) 2 (29)
Clinical severity
 Mild 15 (60)
 Moderate 3 (12)
 Severe 4 (16)
 Death 3 (12)
Delayed development or mental retardation 17 (85)
Regression/deterioration 13 (52)
Oxygen dependency 2 (8)
Enteral tube feeding 4 (16)
Values are presented as median (interquartile range) or number (%).
MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like 
episodes; NAA, N-acetylaspartate.





mutation (-) P value
Increased lactate peak (+) 18/25 4/9 0.138
Decreased NAA peak (+) 17/25 5/9 0.942
MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like 
episodes; NAA, N-acetylaspartate.
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Discussion 
In this study, we evaluated the role of MRS in the initial diagnosis 
of MELAS. Most initial MELAS evaluations begin with a series of 
biochemical studies of blood, urine, and CSF. Elevated lactate lev-
els have long been associated with mitochondrial diseases. False el-
evations of plasma lactate are common because of improper speci-
men collection and handling. An elevated lactate-to-pyruvate ratio 
provides a more useful tool than serum lactate values for indicating 
respiratory chain dysfunction. CSF lactate levels are not influenced 
by the collection technique and are elevated in mitochondrial dis-
order patients with predominant brain manifestations. 
Suomalainen et al. [11] reviewed the sensitivity (52%) and 
specificity (92%) of lactate measurements in patients with geneti-
cally confirmed mitochondrial disease. Blood lactate levels can be 
normal in MELAS patients; however, even in the presence of nor-
mal serum lactate, the CSF lactate level may be a more reliable di-
agnostic marker for MELAS.  
Tsujikawa et al. [12] reported that the concentration of CSF lac-
tate was closely correlated with that of brain tissue lactate obtained 
via MRS. Elevations of brain lactate levels are generally indicative 
of increased anaerobic glycolytic rates. NAA reduction reflects 
neuronal injury and impaired mitochondrial dysfunction after re-
current stroke-like episodes. 
Previous studies have reported that brain metabolites could be 
evaluated using MRS to determine disease progression and per-
form treatment monitoring in patients with mitochondrial disor-
ders [5,13]. Heteroplasmy results in a variety of clinical pheno-
types, from asymptomatic carriers to fully symptomatic patients, 
as well as different mutational burdens between and within tissues. 
Weiduschat et al. [7] recently reported that metabolic abnormali-
ties detected by MRS in asymptomatic A3243G carriers have po-
tential clinical value as biomarkers of disease progression and ther-
apeutic response. A recent study comparing the efficacy of MRS 
after acute neurologic symptoms in patients with acute ischemic 
stroke (AIS) and patients with MELAS found a lactic acid peak in 
only 69.2% of AIS patients, whereas a lactic acid peak was found in 
all patients with MELAS [14,15]. Therefore, MRS findings can re-
flect a lack of energy production due to impaired oxidative phos-
phorylation caused by nonspecific ischemia and hypoxia in the 
acute phase, and the relatively high sensitivity of MRS makes it a 
useful tool for the diagnosis of MELAS patients. 
This study aimed to evaluate the clinical value of non-invasive 
MRS to detect brain metabolites in the initial diagnosis of geneti-
cally confirmed A3243G MELAS patients. Among 34 MELAS 
cases, no significant difference was found for increased lactate 
(P> 0.05) or decreased NAA peaks (P> 0.05) in MRS between 
the groups with and without genetic confirmation. Twenty-five of 
the 34 patients were diagnosed with genetically confirmed ME-
LAS with the A3243G pathogenic mutation. Only 18 (72%) of 
those 25 patients had a lactate peak on initial MRS. 
The detection of a lactate peak on MRS is dependent on the 
timing or severity of the disease. In the 25 genetically confirmed 
MELAS patients, the timing of the initial MRS test was divided 
into groups according to whether MRS was performed in the acute 
stage, despite the limited number of samples, and lactic acid peaks 
were found in all MRS data performed within 2 weeks after the 
first neurologic symptoms. In this study, the neurological symp-
toms of MELAS most commonly presented as stroke-like epi-
sodes, and elevated lactate peaks in MRS were identified in all ME-
LAS patients in the acute stage with or without serum lactic acido-
sis. Elevated lactate peaks in initial MRS were not identified in pa-
tients with resolving first stroke-like symptoms, who showed 
symptoms at least 28 days before MRS. However, elevated lactate 
peaks on MRS and severe diffuse cerebral atrophy on MRI were 
shown in eight of 15 patients who underwent MRS more than 2 
weeks after initial onset, and those patients had at least two recur-
rent stroke-like episodes despite the current absence of acute 
symptoms. Decreased NAA peaks were found in 17 of the 25 ME-
LAS patients. The decreasing trend in NAA concentration reflects 
brain damage due to recurrent stroke-like attacks during prolonged 
periods with or without acute symptoms. 
In conclusion, although initial MRS alone is not enough to defi-
nitely diagnose MELAS, it is worthwhile as a non-invasive comple-
mentary diagnostic tool along with genetic testing, as well as for 
monitoring the disease progress of MELAS. 
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Fig. 1. Increased lactate peaks shown on magnetic resonance 
spectroscopy in mitochondrial encephalomyopathy, lactic acidosis, 
and stroke-like episodes (MELAS; A2343G) patients (n=25).
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